Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

But Hims & Hers' shares fell in after-hours trading as second-quarter projections fell short of analysts' expectations. The ...

With more and more people signing up for weight loss drugs, the potential side effects are starting to attract attention.

The global race for weight loss solutions has firmly arrived in India—bringing with it hope, hype, and a host of unanswered ...

Andrew Dudum; Chairman of the Board, Chief Executive Officer; Hims & Hers Health Inc Oluyemi Okupe; Chief Financial Officer; Hims & Hers Health Inc Good afternoon, ladies and gentlemen. Thank you for ...

A recent study presented at the 2025 International Society for Heart and Lung Transplantation (ISHLT) annual meeting suggests ...

Protein is a cornerstone nutrient for maintaining overall health, but its significance becomes especially prominent for those ...

The WHO's conditional recommendation will be officially released in August, as part of new guidelines on treating obesity. It is also working on separate guidelines for children and adolescents.

The apparent success — and now almost ever-present ubiquity — of GLP-1 receptor agonists in weight loss has led to research, and possible uses, far beyond its initial indications in diabetes, ...

China represents an untapped market for GLP-1 class diabetes drugs, according to Novo Nordisk, which is predicting "good momentum" for its already-approved Victoza, and its successor semaglutide.

The first trial, PIONEER 4, set the new drug against Novo’s own product, injectable once a week Victoza. Semaglutide performed better than expected against Victoza. The results included ...

Though retrospective, the findings provide ‘compelling’ evidence that GLP-1 receptor agonists may help prevent development ...